Bellicum Pharmaceuticals, Inc.
BLCM
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -763.00K | -7.35M | -8.07M | -6.20M | -7.21M |
| Total Depreciation and Amortization | 2.00K | 2.00K | 3.00K | 2.00K | 1.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 110.00K | 347.00K | -15.00K | -423.00K | 744.00K |
| Change in Net Operating Assets | -865.00K | -990.00K | 1.65M | -293.00K | 563.00K |
| Cash from Operations | -1.52M | -7.99M | -6.43M | -6.91M | -5.91M |
| Capital Expenditure | 0.00 | 1.00K | -5.00K | -7.00K | 0.00 |
| Sale of Property, Plant, and Equipment | 15.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 15.00K | 1.00K | -5.00K | -7.00K | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -1.00K | -10.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.50M | -7.99M | -6.44M | -6.92M | -5.92M |